drug pricing · gene therapy
Most Expensive Drugs in the US: A 2025 Price List
October 8, 2025
Updated August 5, 2026
15 min read
See the 2025 list of the most expensive drugs in the USA, led by multi-million dollar gene therapies like Lenmeldy & Elevidys for rare diseases. Learn why price
- 01Lenmeldy holds the highest list price of any U.S. drug at $4.25 million per dose, followed by Kebilidi at $3.95 million.
- 02Nearly all of the priciest U.S. drugs are one-time gene or cell therapies for rare diseases, with list prices ranging from about $2 million up to $4.25 million per patient.
- 03Manufacturers justify multi-million-dollar prices by citing lifetime disease-management costs, such as $4 million to $6 million for chronic sickle cell care.
- 04Payers are managing the risk of one-time, multi-million-dollar therapies with stop-loss insurance, carve-out policies, and manufacturer outcomes-based warranties.
- 05A 2025 Reuters investigation found the median launch price for new U.S. drugs reached $300,000, a 35% jump from 2022, driven by rare-disease treatments.
The United States now leads the world in record‐high drug prices, especially for one-time gene and cell therapies targeting rare diseases. A Reuters analysis found that median list prices for newly launched U.S. drugs more than doubled over four years (to about $300,000 in 2023) as treatments shifted toward orphan diseases ([1]) ([2]). In practice, that shift means single-dose cures are routinely hundreds of times more expensive than conventional drugs. For example, the newly approved gene therapy Lenmeldy (for metachromatic leukodystrophy) carries a list price of $4.25 million per dose ([3]) – the highest price of any U.S. medication to date. (Health economists at ICER noted that this one-time treatment might justify a cost up to ~$3.94 million based on its long-term benefits ([4]).) Other recent examples of “million-dollar” therapies include Bluembird’s Skysona ($3.0 M for X-linked adrenoleukodystrophy) ([5]) and Sarepta’s Elevidys ($3.2 M for Duchenne muscular dystrophy) ([6]). By comparison, traditional specialty drugs (like CAR-T cancer immunotherapies) typically run in the mid-$300,000s per course – still high, but well below these record-breaking therapies.
-
Lenmeldy (atidarsagene autotemcel) – A gene therapy for pediatric metachromatic leukodystrophy (MLD). Approved in 2024, Lenmeldy (from Orchard Therapeutics/Kyowa Kirin) is priced at about $4.25 million per patient ([3]). This therapy targets a deadly nervous-system disease affecting ~1 in 40,000 children; roughly half of late-infantile cases die within five years without treatment ([3]). The manufacturer is arranging outcome-based agreements with insurers, reflecting the drug’s enormous upfront cost and uncertain long-term outcome.
-
Kebilidi (eladocagene exuparvovec) – PTC Therapeutics' gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency, an ultra-rare inherited neurological disorder that leaves children unable to produce enough dopamine and serotonin. Approved by the FDA in November 2024, Kebilidi is administered directly into the brain in a single surgical procedure and carries a list price of $3.95 million, making it the second-most-expensive drug in the U.S. market behind Lenmeldy ([7]). The FDA also awarded PTC Therapeutics a rare pediatric disease priority review voucher for the approval, which the company subsequently sold for $150 million ([7]).
-
Elevidys (delandistrogene moxeparvovec-rokl) – Sarepta’s adeno-associated virus vector-based gene therapy for Duchenne muscular dystrophy (DMD). Its 2023 FDA approval set its price at $3.2 million ([6]) for a single infusion. FDA currently indicates Elevidys for ambulatory patients aged 4 years and older with a confirmed DMD-gene mutation. Its labeling includes a boxed warning for acute serious liver injury and acute liver failure; use in non-ambulatory patients is no longer licensed.
-
Hemgenix (etranacogene dezaparvovec) – A hemophilia B gene therapy by CSL Behring. FDA-approved in 2022, Hemgenix’s one-time infusion is priced at ~$3.5 million ([8]). It is designed to replace regular clotting-factor infusions by enabling patients to produce their own factor IX. At launch Hemgenix was billed as “the world’s most expensive therapy” ([8]), and its cost matches Pfizer’s later hemophilia B therapy below. (Both therapies achieved long-term remission in a majority of trial patients, but insurers and analysts continue to debate the value of the $3.5 M price tag.)
-
Beqvez (etranacogene dezaparvovec-drlb) – Pfizer’s hemophilia B gene therapy (new trade name as of 2024). Approved shortly after Hemgenix, Beqvez was launched at the same $3.5 million price point ([9]), eliminating bleeding in 60% of patients after one year versus 29% for standard care ([9]). The two therapies target the same disorder and hence represent fierce pricing competition: insurers typically will view them interchangeably.
-
Casgevy (exagamglogene autotemcel) – The first FDA-approved therapy built on CRISPR/Cas9 genome-editing technology, developed jointly by Vertex Pharmaceuticals and CRISPR Therapeutics for sickle cell disease. The FDA approved Casgevy on December 8, 2023 for patients 12 and older with recurrent vaso-occlusive crises ([10]). Vertex set the list price at $2.2 million per patient ([11]). Of the 31 evaluable trial patients, 29 (93.5%) achieved freedom from severe vaso-occlusive crises for at least 12 consecutive months ([12]). Vertex and bluebird bio both note that lifetime management of recurrent sickle cell pain crises can cost $4 million to $6 million, a figure the companies use to frame the one-time price as comparable to (or cheaper than) years of chronic care ([11]).
-
Lyfgenia (lovotibeglogene autotemcel) – bluebird bio's lentiviral-vector gene therapy for sickle cell disease, approved the same day as Casgevy for patients 12 and older with a history of vaso-occlusive events ([13]). Lyfgenia carries the highest list price of the two sickle cell gene therapies at $3.1 million ([11]), which bluebird bio says reflects "the value the therapy may deliver through robust and sustained clinical benefits" ([11]). The FDA label carries a black-box warning for hematologic malignancy, requiring lifelong monitoring of treated patients ([14]).
-
Roctavian (valoctocogene roxaparvovec-rvox) – BioMarin Pharmaceutical's one-time AAV5 vector-based gene therapy for adults with severe hemophilia A, FDA-approved June 29, 2023 as the first gene therapy for that indication ([15]). BioMarin priced Roctavian at a wholesale acquisition cost of $2.9 million, positioning it below the $3.5 million charged for hemophilia B gene therapies, and pointed to the roughly $800,000 a year typically spent on factor VIII prophylaxis as the offsetting economic benefit ([16]). BioMarin also offers an outcomes-based warranty reimbursing payers up to 100% of the acquisition cost if a patient does not respond, prorated over the first four years post-dosing ([17]). BioMarin estimates about 2,500 U.S. patients are eligible under the approved label.
-
Skysona (elivaldogene tavalent-l) – A Bluebird (now part of AbbVie) gene therapy for cerebral adrenoleukodystrophy (CALD), a fatal childhood leukodystrophy. Approved in 2022, Skysona costs about $3 million per treatment ([5]). It is indicated for boys (ages 3–12) with very early-stage X-ALD; as a one-time transplant of modified stem cells, it can halt disease in many patients. Because of reported long-term safety signals (cases of leukemia after treatment), the FDA now recommends evaluating alternatives first ([5]), but the price remains among the highest in the U.S.
-
Zynteglo (betibeglogene autotemcel) – A Bluebird Bio gene therapy for transfusion-dependent β-thalassemia. Approved in 2022, Zynteglo is priced at about $2.8 million ([18]) as a one-time procedure. It works by enabling patients’ bone marrow to produce normal hemoglobin, potentially freeing them from lifelong blood transfusions. Zynteglo’s launch price marked it as one of the most expensive U.S. drugs at the time ([18]), and it remains a benchmark for thalassemia treatment costs.
-
Zolgensma (onasemnogene abeparvovec-xioi) – Novartis’ gene therapy for spinal muscular atrophy (SMA). First approved in 2019 for infants, Zolgensma carries a list price of $2.125 million (over $2.1 million) per patient ([19]). This one-time IV gene-replacement therapy is not a cure; FDA approval was based on evidence of improved survival and motor-milestone outcomes in studied infants with SMA. At its launch, Zolgensma was the world’s most expensive drug ([19]), and while newer therapies have surpassed it, it remains an iconic example of a high-cost one-time therapy.
-
Miplyffa (Hydroxypropyl beta-cyclodextrin) – A small-molecule therapy by Zevra Therapeutics for Niemann-Pick disease type C (NPC). Approved in 2024, Miplyffa is taken orally three times daily. The highest labeled dose costs about $106,000 per month, which extrapolates to ~$1.3 million per year ([20]). Even at that price, analysts expect insurers to secure substantial discounts (estimating a net price ~$600k/yr) due to the drug’s critical use in only ~900 U.S. patients ([20]).
Other high-cost therapies: Besides single-dose cures, some multi-dose regimens are also among the most expensive. For context, Spark Therapeutics’ Luxturna (for inherited retinal degeneration) costs ~$850,000 for the two-eye treatment (about $425,000 per eye). Biogen’s spinal muscular atrophy drug Spinraza (three initial doses plus annual maintenance) costs about $750,000 in the first year. Novartis’s CAR-T therapy Kymriah (for acute lymphoblastic leukemia) and Gilead’s Yescarta (for lymphoma) are roughly $475,000 and $373,000 per infusion, respectively. Krystal Biotech’s Vyjuvek (beremagene geperpavec-svdt), the first topical herpes-simplex-vector gene therapy, was FDA-approved in 2023 for wound healing in dystrophic epidermolysis bullosa; because it is applied repeatedly rather than dosed once, published estimates put total lifetime spending on a single patient as high as $15 million ([21]). These are high by traditional standards, but still well below the multi-million-dollar one-time therapies above.
Why These Prices Are So High
- First FDA-approved CRISPR/Cas9 genome-editing therapy, developed jointly by Vertex Pharmaceuticals and CRISPR Therapeutics for sickle cell disease.
- List price set at $2.2 million per patient.
- 29 of 31 evaluable trial patients (93.5%) were free of severe vaso-occlusive crises for at least 12 consecutive months.
- bluebird bio's lentiviral-vector gene therapy for sickle cell disease, approved the same day as Casgevy.
- Carries the highest list price of the two sickle cell gene therapies, at $3.1 million.
- FDA label carries a black-box warning for hematologic malignancy, requiring lifelong monitoring.
Both therapies were approved on December 8, 2023, for patients 12 and older with recurrent vaso-occlusive crises.
Several forces push one-time gene and cell therapies into seven-figure territory. First, the patient populations are tiny by pharmaceutical-industry standards: Lenmeldy's metachromatic leukodystrophy affects roughly 1 in 40,000 children, and sickle cell disease, while far more common at about 100,000 U.S. patients, still represents a fraction of the market for a typical blockbuster pill ([22]). With development costs spread across so few eligible patients, manufacturers argue each dose must recoup a proportionally larger share of R&D spending.
Second, U.S. law gives sponsors of orphan-designated products powerful incentives to develop these therapies, and, indirectly, latitude to price them richly. The FDA's Orphan Drug Act program grants qualifying rare-disease treatments up to seven years of market exclusivity after approval, plus tax credits for clinical trials and exemption from certain user fees ([23]). Nearly every therapy on this list, including Casgevy, Lyfgenia, Roctavian, Hemgenix, and Zolgensma, carries Orphan Drug and often Priority Review, Fast Track, or Regenerative Medicine Advanced Therapy designations, each of which shortened its path to market and reinforced the manufacturer's exclusivity window against biosimilar or generic competition ([24]).
Third, manufacturers consistently frame list prices against the lifetime cost of managing the underlying disease rather than against the cost of manufacturing a single dose. BioMarin points to the roughly $800,000 a year a typical severe hemophilia A patient spends on factor VIII replacement therapy as justification for Roctavian's $2.9 million price ([16]), while Vertex and bluebird bio cite $4 million to $6 million in lifetime sickle cell care costs to justify Casgevy and Lyfgenia ([11]). Critics counter that this "cost offset" framing is difficult to verify prospectively, since it depends on assumptions about how long a cure actually lasts and how much conventional care a given patient would otherwise have needed.
Notably, a high list price does not guarantee commercial success. bluebird bio, the original developer of Zynteglo, Skysona, and Lyfgenia, struggled to build a sustainable market for its three approved gene therapies despite once being valued at more than $10 billion; the company sold itself to a pair of private equity firms in early 2025 for between $29 million and $45 million upfront and was subsequently renamed Genetix Biotherapeutics ([7]). The episode illustrates a recurring tension in this market: multi-million-dollar list prices are meant to recoup R&D costs across a tiny patient population, but slow real-world uptake, reimbursement friction, and the logistical burden of the treatment itself can leave even an FDA-approved cure without a viable commercial path.
Finally, sheer manufacturing complexity plays a role. Autologous ex vivo cell therapies such as Casgevy, Lyfgenia, and Zynteglo require extracting a patient's own cells, genetically modifying them in a specialized facility, and reinfusing them after chemotherapy-based conditioning. This multi-week, highly individualized process is far more resource-intensive than manufacturing a small-molecule pill in bulk ([25]). Elevidys is instead an adeno-associated virus vector-based gene therapy.
Highest list price of any U.S. drug (Lenmeldy, single dose)
List price of Casgevy, the first CRISPR-based gene therapy
Median launch price for a new U.S. drug, 2025 Reuters analysis
Casgevy trial patients free of severe pain crises for 12+ months
The patient's own cells are extracted as the starting material for the therapy.
The extracted cells are genetically modified in a specialized manufacturing facility.
The patient undergoes chemotherapy-based conditioning to prepare the body for reinfusion.
The modified cells are reinfused into the patient after conditioning is complete.
The result is a multi-week, highly individualized process far more resource-intensive than manufacturing a small-molecule pill in bulk.
“The United States now leads the world in record‐high drug prices, especially for one-time gene and cell therapies targeting rare diseases.
How Payers and Insurers Are Managing the Risk
The arrival of dozens of multi-million-dollar one-time therapies (37 cell and gene therapies had been FDA-approved as of mid-2024, with many more in the pipeline) has forced employers, insurers, and reinsurers to rethink how they budget for pharmacy risk ([26]). Because these are classified as one-time medical expenses rather than ongoing drug costs, and because the Affordable Care Act eliminated lifetime dollar limits on health plans, self-insured employers can no longer simply cap their exposure the way they once did ([27]).
The most common risk-management tool is stop-loss insurance (also called medical reinsurance), which protects a self-funded health plan against a single catastrophic claim. Underwriters increasingly build cell-and-gene-therapy-specific pricing into these policies, sometimes applying higher premiums or per-person exclusions ("lasers") for members considered likely to need one of these treatments ([28]). Some plans instead buy a dedicated carve-out policy, a per-member, per-month fee that covers a defined list of gene and cell therapies, often conditioned on using a specific pharmacy benefit manager or plan administrator ([29]).
Manufacturers, for their part, are increasingly willing to share financial risk directly with payers. BioMarin's Roctavian warranty, which refunds up to 100% of the acquisition cost if a patient fails to respond, is one of the more fully developed examples ([17]), and multi-year, milestone-based payment agreements are being discussed industry-wide even though, as one stop-loss specialist put it, "I have not yet heard of any that have actually been leveraged yet" at scale ([30]). Analysts describe the current environment as a "lake wave" ahead of an anticipated "gene therapy tsunami," as rapid FDA approvals continue to outpace real-world patient uptake, which remains slowed by manufacturing capacity, physician hesitancy, and the sheer logistics of chemotherapy-based conditioning regimens ([31]).
“Nevertheless, the era of multi-million-dollar drugs has raised urgent questions about who will pay and how the system will cope with success in curing (rather than treating) rare diseases.
Policy Context and Outlook
These sky-high prices have drawn intense scrutiny. U.S. prescription drug prices are far higher than in other countries, and politicians on both sides of the aisle have criticized the trend. President Biden’s 2022 Inflation Reduction Act empowered Medicare to negotiate prices for certain expensive drugs, though this mostly targets older blockbusters. By late 2025, the Trump administration also took steps: for example, in September 2025 President Trump announced a deal with Pfizer requiring Medicaid prices for Pfizer drugs to match prices in other developed nations ([32]). Meanwhile, industry analysts note that new drug launches increasingly target narrow patient populations, which justifies high prices in company view but raises fairness questions ([2]).
Indeed, a 2025 Reuters investigation reported that the median launch price for a new U.S. drug had reached $300,000 (a 35% jump from 2022), driven by rare-disease treatments ([1]). That same analysis highlighted a handful of extreme cases – for example, Niemann-Pick drug Miplyffa exceeds $1M annually and Lenmeldy costs $4.25M in a single dose ([2]). Policymakers and patient advocates emphasize that prices of this magnitude are unsustainable. Some proposals have emerged, including more aggressive price negotiation or linking prices to international benchmarks. (Notably, President Trump has publicly urged aligning U.S. drug prices with other countries’ levels ([33]).)
At the same time, manufacturers argue that these therapies, though costly, may deliver long-term value by reducing future care costs and improving patient lives. For instance, without treatment, many of these rare diseases are rapidly fatal or cause lifelong disability, which itself incurs high healthcare and societal costs. Outcome-based insurance deals are being explored: if a therapy fails, the manufacturer refund provision could mitigate financial risk. Nevertheless, the era of multi-million-dollar drugs has raised urgent questions about who will pay and how the system will cope with success in curing (rather than treating) rare diseases.
In summary, as of October 2025 the U.S. market’s priciest therapies are predominantly one-time gene or cell treatments for rare disorders, with list prices ranging from roughly $2 million up to $4.25 million per patient ([3]) ([6]). Other high-cost drugs (whether administered once or over time) tend to stay below the million-dollar threshold. This cohort of blockbuster orphan therapies sits at the frontier of medicine – and cost – with broad implications for healthcare budgeting and insurance design. Stakeholders continue to watch closely as new therapies enter the market and as policy efforts aim to rein in costs while rewarding medical innovation.
Sources: Authoritative news reports and analyses, including Reuters and healthcare industry outlets, were used to identify current highest-priced U.S. drugs and therapies ([3]) ([8]) ([5]) ([18]) ([19]) ([6]) ([2]) ([32]) ([20]) ([34]) ([35]) ([36]) ([11]) ([37]) ([38]). These sources provide launch prices, drug descriptions, and context for pricing trends.
Sources / 38
Need Expert Guidance on This Topic?
Let's discuss how IntuitionLabs can help you navigate the challenges covered in this article.
I'm Adrien Laurent, Founder & CEO of IntuitionLabs. With 25+ years of experience in enterprise software development, I specialize in creating custom AI solutions for the pharmaceutical and life science industries.
The information contained in this document is provided for educational and informational purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained herein. Any reliance you place on such information is strictly at your own risk. In no event will IntuitionLabs.ai or its representatives be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from the use of information presented in this document. This document may contain content generated with the assistance of artificial intelligence technologies. AI-generated content may contain errors, omissions, or inaccuracies. Readers are advised to independently verify any critical information before acting upon it. All product names, logos, brands, trademarks, and registered trademarks mentioned in this document are the property of their respective owners. All company, product, and service names used in this document are for identification purposes only. Use of these names, logos, trademarks, and brands does not imply endorsement by the respective trademark holders. IntuitionLabs.ai is an AI software development company specializing in helping life-science companies implement and leverage artificial intelligence solutions. Founded in 2023 by Adrien Laurent and based in San Jose, California. This document does not constitute professional or legal advice. For specific guidance related to your business needs, please consult with appropriate qualified professionals.
Related Articles
Rare Diseases in 2025: Diagnosis, Treatment & Policy
Explore the 2025 rare disease landscape, affecting 300 million people globally. Learn about diagnostic challenges, orphan drug development, and future policy di
Top Biotech Startups 2026: An Analysis of Emerging Trends
An evidence-based analysis of 20 biotech startups poised for impact by 2026. Learn about key innovations in gene therapy, diagnostics, AI, and sustainability.
Medicare Drug Price Negotiation List: All Drugs and Prices
A 2026 analyst guide to the Medicare Drug Price Negotiation list, covering all 40 selected drugs across three rounds, negotiated Maximum Fair Prices, CMS savings estimates, and pending litigation.